d0415ab-0688-51d7-adef-416c0e78b9da
at
ClaimsKG
http://data.gesis.org/claimskg/creative_work/2d0415ab-0688-51d7-adef-416c0e78b9da
Property
Value
?:
author
claimskg:
creative_work_author/a380f583-a7f4-5122-a68f-19264880cf4f
?:
datePublished
2021-08-30
(xsd:date)
is
?:
itemReviewed
of
claimskg:
claim_review/722f7551-9335-5fd6-82ef-f460b1d1d611
?:
mentions
claimskg:
mention/58c9d611-b213-51bc-a94a-0a9d13abce3a
claimskg:
mention/961a4f4c-ff8b-5df0-8773-993124ab153f
claimskg:
mention/97337c76-e61a-5af8-8e5f-dec74d32a88c
claimskg:
mention/f351cee8-348a-5597-b3bd-e436f1196d0a
?:
text
Le Japon a approuvé l'ivermectine comme traitement anti-Covid
(fr)
rdf:
type
<
http://schema.org/CreativeWork
>
![[This page as RDF]](http://data.gesis.org/claimskg/static/rdf-icon.gif){kind=icon}